502 J. Fernández-Ruiz and S. González
Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000a) Enhanced levels of
endocannabinoids in the globus pallidus are associated with a reduction in movement
in an animal model of Parkinson’s disease. FASEB J 14:1432–1438
Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M,
Ramos JA, Fernandez-Ruiz J (2000b) Enhancement of anandamide formation in the
limbic forebrain and reduction of endocannabinoid contents in the striatum of∆9-
tetrahydrocannabinol-tolerant rats. J Neurochem 74:1627–1635
Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, Fernandez-
Ruiz J (2001) Hypolocomotor effects in rats of capsaicin and two long chain capsaicin
homologues. Eur J Pharmacol 420:123–131
Dinh TP, Freund TF, Piomelli D (2002) A role for monoglyceride lipase in 2-arachidonoyl-
glycerol inactivation. Chem Phys Lipids 121:149–158
Factor SA, Friedman JH (1997) The emerging role of clozapine in the treatment of movement
disorders. Mov Disord 12:483–496
Fernández-Espejo E, Caraballo I, Rodríguez de Fonseca F, El Banoua F, Ferrer B, Flores JA,
Galán-Rodríguez B (2004) Homeostatic changes of anandamide synthesis, and func-
tional effects of cannabinoid CB1 antagonists in rats with severe hemiparkinsonism.
Neurobiol Dis (in press)
Fernández-Ruiz J, Lastres-Becker I, Cabranes A, González S, Ramos JA (2002) Endocannabi-
noids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 66:263–
273
Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A (2003) Effects of levodopa on
endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-
induced dyskinesias. Eur J Neurosci 18:1607–1614
Fox SH, Henry B, Hill M, Crossman A, Brotchie J (2002a) Stimulation of cannabinoid re-
ceptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate
model of Parkinson’s disease. Mov Disord 17:1180–1187
Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM (2002b) Randomised, double-blind,
placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in
the treatment of dystonia. Mov Disord 17:145–149
Francis PT, Webster MT, Chesell IP, Holmes C, Stratmann GC, Procter AW, Cross AJ,
Green AR, Bouen DM (1993) Neurotransmitters and second messengers in aging and
Alzheimer’s disease. Ann NY Acad Sci 695:19–26
Fride E, Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist,
anandamide, a brain constituent. Eur J Pharmacol 231:313–314
Gerdeman G, Lovinger DM (2001) CB1 cannabinoid receptor inhibits synaptic release of
glutamate in rat dorsolateral striatum. J Neurophysiol 85:468–471
Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D (1999)
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat
Neurosci 2:358–363
Giuffrida A, Beltramo M, Piomelli D (2001) Mechanisms of endocannabinoid inactivation:
biochemistry and pharmacology. J Pharmacol Exp Ther 298:7–14
Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG (2003) Evidence
against the presence of an anandamide transporter. Proc Natl Acad Sci USA 100:4269–
4274
Glass M, Faull RLM, Dragunow M (1993) Loss of cannabinoid receptors in the substantia
nigra in Huntington’s disease. Neuroscience 56:523–527
Glass M, Dragunow M, Faull RLM (2000) The pattern of neurodegeneration in Huntington’s
disease: a comparative study of cannabinoid, dopamine, adenosine and GABA-A re-
ceptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience
97:505–519
González S, Romero J, de Miguel R, Lastres-Becker I, Villanúa MA, Makriyannis A, Ramos
JA, Fernández-Ruiz J (1999) Extrapyramidal and neuroendocrine effects of AM404, an
inhibitor of the carrier-mediated transport of anandamide. Life Sci 65:327–336